Department of Experimental Medicine and Biotechnology, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
Mol Cell Biochem. 2009 Nov;331(1-2):187-92. doi: 10.1007/s11010-009-0157-7. Epub 2009 May 17.
Both idiopathic restrictive cardiomyopathy (IRCM) and hypertrophic cardiomyopathy (HCM) are part of the same disease spectrum and are due to sarcomeric gene mutations. A patient with restrictive physiology without left ventricular hypertrophy (LVH) would be diagnosed as IRCM, while one with LVH would be diagnosed as HCM with restrictive physiology. We studied a group of patients with restrictive physiology for mutations in beta-myosin heavy chain (MYH7) and troponin I (TNNI3) gene. Consecutive probands in the HCM and IRCM cohort over a 4-year period were considered for this study. These included 10 IRCM and 102 HCM patients. All were Asian Indians. Among the 17 patients who had restrictive physiology 10 were IRCM patients and seven were HCM patients. Of the HCM patients, seven (6.9%) had restrictive physiology. Mean age of these 17 patients was 40.1 +/- 19.2 years (range: 15-67 ), six (35.3%) were males. Maximal left ventricular wall thickness of the seven HCM probands was 20.7 +/- 5.2 mm (range: 16-31), while it was normal in the IRCM probands. Ten probands (58.8%) were in NYHA class III or IV. Seven patients (41.2%) had atrial fibrillation. All the probands were screened for mutations in selected exons of MYH7 and TNNI3 genes. One IRCM patient was found to have p.Arg721Lys mutation in the MYH7 gene. She died due to progressive congestive cardiac failure at the age of 47 years. One HCM proband with a maximal left ventricular wall thickness of 17 mm had p.Arg192His mutation in the TNNI3 gene. She had features consistent with restrictive physiology. Her father and sister had died of restrictive cardiomyopathy. IRCM and HCM with restrictive physiology, both are part of the clinical expression of MYH7 and TNNI3 mutations and lead to worse clinical onset and progression of the disease.
特发性限制型心肌病 (IRCM) 和肥厚型心肌病 (HCM) 均属于同一疾病谱,是由肌节基因突变引起的。无左心室肥厚 (LVH) 的限制型生理患者将被诊断为 IRCM,而有 LVH 的患者将被诊断为具有限制型生理的 HCM。我们研究了一组限制型生理的患者,检测他们的β-肌球蛋白重链 (MYH7) 和肌钙蛋白 I (TNNI3) 基因突变。在四年的时间里,连续入选 HCM 和 IRCM 队列中的先证者进行这项研究。这包括 10 例 IRCM 和 102 例 HCM 患者。所有患者均为亚洲裔印度人。在 17 例具有限制型生理的患者中,10 例为 IRCM 患者,7 例为 HCM 患者。在 HCM 患者中,有 7 例 (6.9%) 具有限制型生理。这 17 名患者的平均年龄为 40.1 +/- 19.2 岁 (范围:15-67),其中 6 名 (35.3%) 为男性。7 例 HCM 先证者的最大左心室壁厚度为 20.7 +/- 5.2mm (范围:16-31),而 IRCM 先证者的左心室壁厚度正常。10 名先证者 (58.8%) 处于纽约心脏协会 (NYHA) 心功能分级 III 或 IV 级。7 名患者 (41.2%) 患有心房颤动。所有先证者均筛查了 MYH7 和 TNNI3 基因的选定外显子突变。一名 IRCM 患者在 MYH7 基因中发现 p.Arg721Lys 突变。她在 47 岁时因进行性充血性心力衰竭而死亡。一名最大左心室壁厚度为 17mm 的 HCM 先证者在 TNNI3 基因中发现 p.Arg192His 突变。她具有限制型生理的特征。她的父亲和妹妹因限制型心肌病而死亡。IRCM 和具有限制型生理的 HCM 均属于 MYH7 和 TNNI3 突变的临床表现的一部分,导致疾病的临床发作和进展更差。